Cargando…
Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients
The gut microbiome acts as a tumor-extrinsic regulator of responses to immune-checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 receptors. Primary resistance to anti-PD-1 ICI can be reversed via responder-derived fecal microbiota transplant (FMT) in patients with refractory melanoma. Efforts to...
Autores principales: | Fortman, Dylan, Avellan, Maria G. Pazan, Hurd, Drew, Schwartz, Marc, Dubner, Howard, Hewitt, Corey, Berton, Samantha, Ernst, Scarlett, Rose, Amy, Zarour, Hong Wangd, Hassane, Davar, Diwakar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949524/ https://www.ncbi.nlm.nih.gov/pubmed/36806616 http://dx.doi.org/10.1097/CMR.0000000000000871 |
Ejemplares similares
-
Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy
por: Davar, Diwakar, et al.
Publicado: (2022) -
A retrospective analysis of the impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma
por: Shaikh, Saba S., et al.
Publicado: (2022) -
Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
por: Bastacky, Melissa L., et al.
Publicado: (2021) -
Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
por: Shaikh, Saba S., et al.
Publicado: (2022) -
Targeting multiple inhibitory receptors to reverse melanoma-induced T cell dysfunction
por: Zarour, Hassane M
Publicado: (2015)